1 The compound has goitrogenic activity in vivo (i.e. thyroid follicular hypertrophy and
hyperplasia).
2 There are clinical chemistry indications of changes in thyroid and pituitary function
(i.e. reduced thyroid hormone and increased TSH plasma concentration).
3 There is specific evidence that the agent either reduces thyroid hormone synthesis (e.g.
inhibits iodine uptake) or increases thyroid hormone clearance (e.g. enhanced biliary
excretion).
4 A progression of lesions in studies of various duration, showing cellular hypertrophy
and hyperplasia, nodular hyperplasia, and neoplasia (benign and possible malignant
tumours) can be demonstrated.